You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,658,785


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,658,785
Title: Adeno-associated virus materials and methods
Abstract:The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.
Inventor(s): Johnson; Philip R. (Gahanna, OH)
Assignee: Children\'s Hospital, Inc. (Columbus, OH)
Application Number:08/254,358
Patent Claims:1. A mammalian host cell stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes.

2. The mammalian host cell of claim 1 wherein said recombinant adeno-associated virus genome comprises adeno-associated virus inverted terminal repeats flanking DNA sequences encoding an immunodeficiency virus protein operably linked to promoter and polyadenylation sequences.

3. The mammalian host cell of claim 1 wherein said recombinant adeno-associated virus genome comprises adeno-associated virus inverted terminal repeats flanking DNA sequences operatively linked to promoter and polyadenylation sequences wherein said DNA sequences encode a polypeptide selected from the group consisting of tyrosine hydroxylase, anomatic amino acid decarboxylase, nerve growth factor, brain derived neurotrophic factor, NT-3, NT-4/5, glial derived neurotrophic factor and fibroblast growth factor.

4. A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a host cell according to claim 1 with a helper virus of adeno-associated virus, thereby producing infectious recombinant adeno-associated virus from said host cell.

5. The mammalian host cell of claim 2 which is HeLa cell line A64 (ATCC CRL 11639).

6. A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a host cell according to claim 2 with a helper virus of adeno-associated virus, thereby producing infectious recombinant adeno-associated virus from said host cell.

7. The mammalian host cell of claim 2, wherein said adeno-associated virus genome comprises the cytomegalovirus (CMV) immediate early promoter, the rabbit-globin intron, the human immunodeficiency virus rev/envelope sequences, and the rabbit-globin poly-adenylation signal.

8. A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a host cell according to claim 3 with a helper virus of adeno-associated virus, thereby producing infectious recombinant adeno-associated virus from said host cell.

Details for Patent 5,658,785

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.